Lexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) Altman Z-score
Lexicon Pharmaceuticals, Inc.'s Altman Z-score for fiscal 2025 is −12.11, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −12.11 | (2.55) |
| FY2024 | −9.56 | 1.43 |
| FY2023 | −11.00 | (1.02) |
| FY2022 | −9.98 | (8.02) |
| FY2021 | −1.96 | 2.87 |
| FY2020 | −4.82 | (3.88) |
| FY2019 | −0.95 | 5.35 |
| FY2018 | −6.29 | (3.43) |
| FY2017 | −2.87 | (1.67) |
| FY2016 | −1.20 | (2.04) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.44 | — | 0.53 | |
| Retained earnings / total assets | (10.91) | — | −15.27 | |
| EBIT / total assets | (0.26) | — | −0.87 | |
| Market value of equity / total liabilities | 5.39 | — | 3.23 | |
| Sales / total assets | 0.27 | — | 0.27 | |
| Altman Z-score | Distress zone | −12.11 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −33.00 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| FDMT 4D Molecular Therapeutics, Inc. compare | 2.5× |
| OABI OmniAb, Inc. compare | 2.5× |
| IVA Inventiva S.A. Sponsored ADR compare | −1.4× |
| ACHV Achieve Life Sciences, Inc. compare | −3.4× |
| LXRX Lexicon Pharmaceuticals, Inc. | −12.1× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | −22.1× |
| SANA Sana Biotechnology, Inc. compare | — |
| IMMX Immix Biopharma, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets